CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets

Blood

Volumn 115, Issue 2, 2010, Pages 274-281

  Yu, Jianhua ^a,b   Mao, Hsiaoyin C ^a   Wei, Min ^a   Hughes, Tiffany ^a   Zhang, Jianying ^a   Park, Il Kyoo ^a   Liu, Shujun ^a,b   McClory, Susan ^a   Marcucci, Guido ^a,b,c   Trotta, Rossana ^a,b   Caligiuri, Michael A ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; L SELECTIN; MONOKINE; PERFORIN; STAT4 PROTEIN; KLRD1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY D; STAT4 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; CELL KILLING; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURFACE PROPERTY; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION REGULATION; IMMUNOLOGY; PHOSPHORYLATION;

ANTIGENS, CD56; CELL DIFFERENTIATION; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; KILLER CELLS, NATURAL; L-SELECTIN; LYMPHOCYTE SUBSETS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY D; PHOSPHORYLATION; STAT4 TRANSCRIPTION FACTOR;

EID: 75649122988     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-215491     Document Type: Article

References (33)

1. Liu CC, Perussia B, Cohn ZA, Young JD. Identification and characterization of a pore-forming protein of human peripheral blood natural killer cells. J Exp Med. 1986;164(6):2061-2076.
2. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A. 2000;97(6):2731-2736.
3. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2(11): 850-861.
4. Dorner BG, Smith HR, French AR, et al. Coordinate expression of cytokines and chemokines by NK cells during murine cytomegalovirus infection. J Immunol. 2004;172(5):3119-3131.
5. Luci C, Reynders A, Ivanov II, et al. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol. 2009;10(1):75-82.
6. Cella M, Fuchs A, Vermi W, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009; 457(7230):722-725.
7. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity. 2008;29(6):947-957.
8. Hughes T, Becknell B, McClory S, et al. Stage three immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH17 cytokine interleukin-22. Blood. 2009;113(17):4008-4010.
9. Cooper MA, Colonna M, Yokoyama WM. Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Rep. 2009;10(10): 1103-1110.
10. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity. 2009;31(1):15-23.
11. Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity. 2008;29(6):958-970.
12. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. 2006;214:56-72.
13. Freud AG, Yokohama A, Becknell B, et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med. 2006; 203(4):1033-1043.
14. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97(10):3146-3151.
15. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol. 1989; 143(10):3183-3191.
16. Chan A, Hong DL, Atzberger A, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol. 2007;179(1):89-94.
17. Ouyang Q, Baerlocher G, Vulto I, Lansdorp PM. Telomere length in human natural killer cell subsets. Ann N Y Acad Sci. 2007;1106:240-252.
18. Romagnani C, Juelke K, Falco M, et al. CD56brightCD16- killer Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol. 2007;178(8):4947-4955.
19. Chang C, Rodriguez A, Carretero M, Lopez-Botet M, Phillips JH, Lanier LL. Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily. Eur J Immunol. 1995;25(9):2433-2437.
20. Borrego F, Masilamani M, Marusina AI, Tang X, Coligan JE. The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance. Immunol Res. 2006;35(3):263-278.
21. Yu J, Wei M, Becknell B, et al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity. 2006;24(5): 575-590.
22. Kim S, Iizuka K, Kang HS, et al. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol. 2002;3(6):523-528.
23. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633-640.
24. Vossen MT, Matmati M, Hertoghs KM, et al. CD27 defines phenotypically and functionally different human NK-cell subsets. J Immunol. 2008;180(6): 3739-3745.
25. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41-101.
26. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006; 176(3):1517-1524.
27. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-469.
28. Frey M, Packianathan NB, Fehniger TA, et al. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol. 1998;161(1):400-408.
29. Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101(8): 3052-3057.
30. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol. 2004;4(4):392-397.
31. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol. 2001;19:423-474.
32. Ohteki T. Critical role for IL-15 in innate immunity. Curr Mol Med. 2002;2(4):371-380.
33. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139-156.